background
respiratori
viru
infect
common
caus
hospitalis
adult
rapid
pointofcar
test
poct
respiratori
virus
might
improv
clinic
care
reduc
unnecessari
antibiot
use
shorten
length
hospit
stay
improv
influenza
detect
treatment
rationalis
isol
facil
use
howev
insuffici
evid
exist
support
use
standard
clinic
care
aim
assess
effect
routin
poct
broad
rang
clinic
outcom
includ
antibiot
use
pragmat
parallelgroup
openlabel
randomis
control
trial
enrol
adult
age
year
within
h
present
emerg
depart
acut
medic
unit
larg
uk
hospit
acut
respiratori
ill
fever
higher
day
durat
two
winter
season
patient
randomli
assign
via
internetbas
alloc
sequenc
random
permut
block
molecular
poc
test
respiratori
virus
routin
clinic
care
primari
outcom
proport
patient
receiv
antibiot
hospitalis
day
secondari
outcom
includ
durat
antibiot
proport
patient
receiv
singl
dose
brief
cours
antibiot
length
stay
antivir
use
isol
facil
use
safeti
analysi
modifi
intent
treat
exclud
patient
declin
intervent
withdrawn
protocol
violat
studi
regist
isrctn
number
complet
enrol
patient
assign
poct
routin
care
six
patient
withdrew
protocol
violat
patient
poct
group
receiv
antibiot
compar
control
differ
ci
mean
durat
antibiot
differ
group
day
sd
poct
group
vs
day
control
group
differ
ci
patient
treat
antibiot
poct
group
receiv
singl
dose
brief
cours
antibiot
h
compar
patient
control
group
differ
ci
number
need
mean
length
stay
shorter
poct
group
day
sd
control
group
day
differ
ci
appropri
antivir
treatment
influenzaposit
patient
common
poct
group
patient
control
group
patient
differ
ci
number
need
found
differ
advers
outcom
group
patient
poct
group
vs
patient
control
group
interpret
routin
use
molecular
poct
respiratori
virus
reduc
proport
patient
treat
antibiot
howev
primari
outcom
measur
fail
captur
differ
antibiot
use
mani
patient
start
antibiot
result
poct
could
made
avail
although
poct
associ
reduct
durat
antibiot
overal
patient
poct
group
receiv
singl
dose
brief
cours
antibiot
patient
control
group
poct
also
associ
reduc
length
stay
improv
influenza
detect
antivir
use
appear
safe
acut
respiratori
tract
infect
respons
huge
burden
diseas
third
common
caus
death
worldwid
although
bacteria
previous
consid
princip
aetiolog
agent
sever
respiratori
tract
infect
global
import
anc
respiratori
virus
group
increasingli
recognis
recent
year
around
emerg
hospit
admiss
acut
respiratori
infect
includ
exacerb
chronic
lung
diseas
occur
england
approxim
death
recent
larg
studi
use
modern
molecular
diagnost
test
shown
respiratori
virus
detect
around
hospitalis
adult
acut
respiratori
ill
test
respiratori
virus
hospitalis
adult
done
basi
clinic
suspicion
rather
routin
reli
laboratorybas
pcr
test
although
highli
accur
turnaround
time
laboratori
pcr
uk
gener
h
requir
specialist
centralis
laboratori
facil
previous
pointofcar
test
poct
respiratori
virus
mainli
limit
antigenbas
test
influenza
test
insuffici
sensit
especi
adult
randomis
control
trial
fail
show
clinic
health
econom
benefit
hospitalis
adult
acut
respiratori
ill
rapid
molecular
test
platform
respiratori
virus
develop
broadli
equival
diagnost
accuraci
laboratori
pcr
platform
potenti
deploy
poc
test
one
platform
us
food
drug
administrationapprov
european
conformitymark
filmarray
respiratori
panel
biofir
salt
lake
citi
ut
usa
test
comprehens
rang
virus
rel
simpl
use
give
result
h
antimicrobi
resist
arguabl
one
greatest
threat
global
human
health
driven
overus
antibiot
antibiot
prescrib
patient
hospitalis
acut
respiratori
ill
includ
clinic
group
virus
strongli
implic
caus
evid
benefit
exist
patient
asthma
exacerb
patient
exacerb
copd
diagnost
uncertainti
regard
microbi
aetiolog
contribut
practic
potenti
benefit
molecular
poct
virus
hospit
includ
reduct
unnecessari
antibiot
use
import
potenti
benefit
poct
includ
reduct
hospit
length
stay
improv
influenza
detect
subsequ
direct
rather
empir
antivir
use
rationalis
hospit
isol
facil
ever
highqual
evid
exist
support
use
molecular
poct
aim
address
evid
gap
pragmat
randomis
control
trial
evalu
effect
routin
molecular
poct
adult
present
hospit
acut
respiratori
ill
broad
rang
clinic
outcom
larg
pragmat
parallelgroup
openlabel
singlecentr
randomis
control
superior
trial
larg
uk
hospit
trial
took
place
two
success
winter
season
patient
recruit
acut
medic
unit
emerg
depart
southampton
gener
hospit
larg
teach
hospit
south
uk
serv
popul
secondari
care
run
trial
sponsor
univers
hospit
southampton
foundat
evid
studi
search
pubm
cochran
control
clinic
trial
regist
clinicaltrialsgov
databas
relev
publish
articl
ongo
trial
assess
clinic
effect
rapid
molecular
test
molecular
pointofcar
test
poct
respiratori
virus
hospitalis
adult
acut
respiratori
ill
use
search
term
pointofcar
test
rapid
pcr
test
rapid
test
viral
test
respiratori
viru
influenza
hospit
adult
clinic
trial
randomis
control
trial
studi
limit
search
studi
publish
jan
nov
english
exclud
studi
use
antigenbas
test
respiratori
virus
studi
children
studi
report
diagnost
accuraci
found
cochran
systemat
review
adult
found
highqual
randomis
control
trial
molecular
poct
evalu
clinic
outcom
found
one
small
randomis
control
trial
evalu
effect
rapid
pointofcar
molecular
test
virus
combin
procalcitonin
test
antibiot
use
hospitalis
adult
nonpneumon
lower
respiratori
tract
infect
found
one
retrospect
cohort
studi
evalu
influenza
detect
neuraminidas
inhibitor
use
rapid
pointofcar
molecular
test
influenza
hospitalis
adult
knowledg
studi
first
larg
randomis
control
trial
evalu
use
routin
molecular
poct
respiratori
virus
hospitalis
adult
acut
respiratori
ill
first
report
comprehens
wide
rang
clinic
outcom
pragmat
design
broad
inclus
criteria
simpl
intervent
make
result
highli
generalis
similar
centr
set
although
poct
associ
reduct
proport
patient
treat
antibiot
lead
greater
proport
patient
treat
singl
dose
brief
cours
antibiot
compar
routin
clinic
care
find
studi
consist
previou
studi
suggest
potenti
benefit
rapid
molecular
test
respiratori
virus
adult
term
reduct
unnecessari
antibiot
use
improv
detect
rate
influenza
improv
neuraminidas
inhibitor
use
studi
suggest
routin
poct
lead
improv
rate
respiratori
viru
detect
improv
antivir
use
influenza
rationalis
hospit
isol
facil
reduct
length
stay
safe
find
confirm
studi
support
health
econom
analysi
show
costeffect
routin
poct
respiratori
virus
becom
part
standard
care
adult
present
hospit
acut
respiratori
ill
nh
trust
southampton
uk
studi
approv
north
westpreston
region
ethic
committe
elig
patient
age
year
older
capac
give
inform
written
consent
abl
will
adher
studi
procedur
patient
southampton
gener
hospit
acut
medic
unit
emerg
depart
could
recruit
studi
within
h
first
triag
emerg
depart
staff
within
h
arriv
acut
medic
unit
admit
directli
unit
acut
respiratori
ill
fever
higher
durat
ill
less
equal
day
episod
acut
respiratori
ill
defin
acut
pulmonari
ill
includ
pneumonia
bronchiti
nonpneumon
lower
respiratori
tract
fection
influenzalik
ill
acut
exac
bation
chronic
respiratori
ill
includ
exac
bation
copd
asthma
bronchiectasi
exclus
criteria
palli
approach
taken
treat
clinician
patient
declin
nasal
pharyng
swab
previou
inclus
studi
origin
exclus
criterion
second
winter
season
modifi
juli
permit
inclus
patient
previous
recruit
repres
day
hospit
discharg
particip
gave
written
inform
consent
immedi
enrol
patient
consecut
assign
uniqu
particip
identif
number
studi
team
member
njb
akm
la
rh
sa
en
use
internetbas
randomis
servic
seal
envelopewhich
use
random
permut
block
size
gener
alloc
sequenc
assign
particip
either
inter
vention
group
control
group
trial
particip
search
staff
clinic
care
provid
blind
group
alloc
data
analyst
blind
group
alloc
particip
randomli
alloc
intervent
group
nose
throat
swab
taken
research
staff
njb
akm
la
rh
sa
en
accord
standard
protocol
analys
immedi
use
filmarray
respiratori
panel
panel
detect
follow
virus
influenza
influenza
b
respiratori
syncyti
viru
rhinoviru
enteroviru
without
specifi
human
metapneumoviru
parainfluenza
viru
type
coronavirus
adenoviru
test
unit
locat
acut
medic
unit
emerg
depart
respiratori
viru
detect
clinic
infect
control
team
inform
directli
result
posit
neg
record
medic
note
patient
randomli
alloc
control
group
manag
accord
routin
clinic
care
use
antibiot
influenza
antivir
isol
facil
base
judgment
respons
clinic
team
test
respiratori
virus
laboratori
pcr
discret
laboratori
pcr
done
use
convent
method
centralis
laboratori
facil
detect
follow
virus
influenza
influenza
b
respiratori
syncyti
viru
human
metapneumoviru
parainfluenza
viru
type
adenoviru
clinic
manag
decis
made
independ
respons
clinic
team
demograph
clinic
data
collect
recruit
outcom
data
collect
retrospect
paper
case
note
electron
medic
record
electron
prescrib
system
data
collect
standard
case
report
form
primari
outcom
measur
proport
patient
treat
antibiot
hospitalis
within
day
admiss
patient
still
hospitalis
whichev
shortest
chose
outcom
public
cochran
review
clinic
effect
poct
influenza
children
conclud
exist
evid
insuffici
make
recommend
random
ise
control
trial
urgent
need
antibiot
use
outcom
measur
addit
small
nonrandomis
studi
suggest
reduct
proport
patient
prescrib
antibiot
test
influenza
poct
captur
entir
rang
clinic
relev
antibiot
chang
associ
poct
select
follow
key
secondari
outcom
measur
durat
antibiot
use
cutoff
day
proport
patient
receiv
singl
dose
antibiot
proport
patient
receiv
less
h
antibiot
proport
patient
receiv
intraven
antibiot
durat
intraven
anti
biotic
cutoff
day
aim
trial
evalu
potenti
clinic
benefit
poct
respiratori
virus
antibiot
use
nonantibiot
secondari
outcom
measur
proport
patient
admit
hospit
length
stay
proport
patient
prolong
inpati
stay
defin
day
turnaround
time
respiratori
viru
test
proport
patient
virus
detect
proport
patient
fluenza
detect
proport
patient
confirm
influenza
treat
neuraminidas
inhibitor
pro
portion
neuraminidas
inhibitor
use
occur
patient
confirm
influenza
time
neur
aminidas
inhibitor
use
durat
neur
aminidas
inhibitor
use
proport
patient
admit
hospit
side
room
durat
side
room
use
time
isol
deisol
durationbas
endpoint
prespecifi
choic
mean
median
depend
variou
factor
includ
distribut
sampl
size
made
data
collect
outcom
measur
discharg
hospit
first
day
hospitalis
whichev
shorter
durat
includ
antibiot
anti
viral
patient
seal
envelop
see
http
sealedenvelopecom
discharg
seriou
advers
event
report
sponsor
per
regulatori
requir
ment
safeti
outcom
admiss
respiratori
highdepend
unit
gener
intens
care
unit
hospitalis
represent
without
admiss
hospit
readmiss
hospit
death
within
day
enrol
base
sampl
size
primari
outcom
measur
proport
patient
treat
antibiot
assum
patient
would
treat
antibiot
detect
reduct
antibiot
use
power
signific
level
patient
would
requir
group
base
test
without
continu
correct
allow
withdraw
rate
set
target
recruit
patient
per
group
patient
total
owe
small
proport
patient
withdrew
randomis
fact
drawal
predominantli
due
breach
inclus
criteria
decis
made
primari
safeti
analys
modifi
intent
treat
analys
done
use
prism
version
graphpad
softwar
la
jolla
ca
usa
stata
version
statacorp
colleg
station
tx
usa
baselin
characterist
group
summaris
use
appropri
descript
statist
initi
compar
primari
outcomeantibiot
usebetween
group
intervent
control
use
differ
proport
un
adjust
odd
ratio
assess
effect
group
primari
outcom
use
multipl
logist
regress
control
follow
covari
demo
graphic
age
sex
influenza
vaccin
statu
durat
symptom
receipt
antibiot
present
comorbid
temperatur
creactiv
protein
concen
tration
clinic
group
compar
durat
antibiot
use
record
hour
analys
present
day
group
use
mean
differ
un
adjust
rate
ratio
assess
effect
group
use
adjust
rate
ratio
multipl
neg
binomi
regress
control
covari
multipl
logist
regress
secondari
outcom
compar
intervent
control
group
use
differ
proport
binari
data
test
mannwhitney
u
test
continu
data
eg
turnaround
time
appropri
choic
latter
two
test
base
distribut
observ
data
sampl
size
ci
present
stata
version
default
use
view
deliber
broad
inclus
criteria
anticip
heterogen
treatment
effect
among
differ
clinic
group
priori
preplan
subgroup
analysi
primari
certain
key
secondari
outcom
measur
basi
diagnost
group
eg
exacerb
asthma
exacerb
copd
pneumonia
assess
result
antibiot
use
includ
use
singl
dose
use
h
durat
durat
antibiot
admiss
length
hospitalis
separ
diagnost
subgroup
assess
interact
clinic
subgroup
group
gression
model
describ
origin
analysi
plan
includ
interact
clinic
group
trial
arm
multipl
logist
regress
howev
model
unstabl
possibl
due
size
subgroup
instead
present
unadjust
comparison
subgroup
owe
natur
analys
mani
comparison
made
result
interpret
cautious
result
present
relat
absolut
differ
mean
proport
studi
prospect
regist
isrctn
number
studi
conduct
hospit
partnership
studi
funder
funder
studi
role
studi
design
data
collect
data
analysi
data
interpret
write
report
correspond
author
full
access
data
studi
final
respons
decis
submit
public
recruit
patient
two
season
jan
april
oct
april
assess
patient
elig
stop
trial
patient
recruit
figur
patient
randomli
assign
receiv
poct
randomli
assign
receiv
routin
clinic
care
control
one
patient
assign
poct
declin
swab
receiv
intervent
one
patient
poct
group
four
control
group
withdrawn
due
protocol
violat
figur
patient
poct
group
patient
routin
clinic
care
group
analys
modifi
intentiontotreat
analysi
figur
baselin
demo
graphic
clinic
characterist
seem
similar
group
tabl
patient
poct
group
test
respiratori
virus
compar
patient
control
group
tabl
patient
poct
group
respiratori
viru
detect
control
group
tabl
mean
turnaround
time
time
decis
test
patient
result
avail
clinician
respiratori
viru
test
substanti
lower
poct
group
tabl
posit
neg
agreement
poct
result
laboratori
pcr
patient
poct
group
done
given
appendix
p
primari
outcom
patient
poct
group
receiv
antibiot
admiss
compar
patient
control
group
differ
favour
control
group
ci
tabl
multipl
logist
regress
analysi
primari
outcom
alter
direct
differ
chang
broader
interpret
tabl
appendix
p
full
result
multipl
logist
regress
model
mean
durat
antibiot
differ
group
differ
tabl
multipl
neg
binomi
regress
analysi
signifi
cantli
alter
interpret
result
tabl
similarli
greater
proport
patient
poct
group
receiv
brief
cours
h
antibiot
control
group
tabl
pro
portion
patient
treat
intraven
antibiot
durat
differ
group
tabl
owe
hospit
process
care
mani
recruit
patient
antibiot
prescrib
earli
cours
assess
often
could
randomli
alloc
poct
result
avail
clinic
team
poct
group
therefor
posthoc
analysi
patient
antibiot
prescrib
randomis
poct
result
avail
clinic
team
subgroup
antibiot
prescrib
patient
poct
group
compar
control
group
differ
ci
number
need
test
prevent
one
patient
treat
antibiot
eight
appendix
p
patient
present
secondari
care
hospitalis
group
tabl
mean
hospit
length
stay
shorter
poct
group
control
group
tabl
proport
patient
prolong
inpati
stay
day
differ
group
posthoc
analysi
antibiot
durat
hospit
length
stay
intervent
group
poct
result
show
patient
posit
result
receiv
shorter
cours
anti
biotic
exacerb
asthma
copd
subgroup
mean
durat
antibiot
lower
patient
poct
group
control
group
nonsignific
differ
observ
subgroup
appendix
pp
patient
asthma
treat
antibiot
greater
proport
patient
poct
group
control
group
receiv
singl
dose
antibiot
tabl
patient
infect
exacerb
copd
treat
antibiot
greater
proport
patient
poct
group
control
group
receiv
less
h
antibiot
distribut
antibiot
durat
asthma
copd
subgroup
see
appendix
pp
patient
infect
exacerb
copd
mean
length
hospit
stay
lower
poct
group
control
group
mean
length
hospit
stay
differ
within
subgroup
tabl
appendix
pp
differ
observ
number
patient
treat
neuraminidas
inhibitor
tabl
greater
proport
patient
treat
neuraminidas
hibitor
poct
group
confirm
influenza
infect
control
group
tabl
addit
patient
treat
empir
neuraminidas
inhibitor
test
neg
influenza
receiv
shorter
cours
neuraminidas
inhibitor
poct
group
compar
control
group
tabl
uk
public
health
england
guidelin
recommend
neuraminidas
inhibitor
treatment
hospitalis
adult
influenza
greater
proport
hospitalis
patient
confirm
influenza
poct
group
treat
neuraminidas
inhibitor
control
group
tabl
mean
time
start
neuraminidas
inhibitor
treatment
patient
differ
group
tabl
data
isol
facil
use
avail
second
year
recruit
winter
owe
introduct
new
hospit
inform
system
allow
hospit
side
room
use
accur
track
real
time
nearest
whole
day
overal
isol
facil
use
differ
group
tabl
howev
greater
proport
patient
poct
group
isol
confirm
respiratori
viru
infect
compar
control
group
tabl
proport
influenzaposit
patient
admit
hospit
stay
least
h
isol
differ
significantli
group
tabl
mean
time
isol
influenzaposit
patient
empir
isol
present
significantli
shorter
poct
group
control
group
mean
time
deisol
patent
initi
isol
suspect
influenza
sub
sequent
test
neg
tabl
found
differ
group
overal
rate
advers
outcom
individu
rate
high
depend
intens
care
unit
admiss
hospitalis
represent
readmiss
hospit
within
day
discharg
mortal
tabl
control
larg
pragmat
randomis
control
trial
first
knowledg
report
effect
routin
molecular
poct
virus
broad
rang
clinic
outcom
includ
antibiot
use
length
hospit
stay
influenza
antivir
use
isol
facil
use
safeti
result
show
routin
molecular
poct
strategi
adult
present
secondari
care
acut
respiratori
ill
led
higher
detect
rate
virus
faster
turnaround
time
result
data
n
mean
sd
median
report
appendix
complet
poctpointofcar
test
hospitalis
influenzaposit
patient
given
twice
daili
room
data
avail
second
season
studi
pcot
control
influenza
respiratori
syncyti
viru
patient
empir
isol
admiss
subsequ
found
influenza
posit
patient
isol
empir
admiss
suspect
influenza
infect
subsequ
found
influenza
neg
tabl
neuraminidas
inhibitor
use
hospit
isol
facil
use
compar
laboratori
pcr
reduc
proport
patient
treat
antibiot
overal
durat
antibiot
compar
routin
clinic
care
howev
lead
increas
proport
patient
receiv
singl
dose
brief
h
cours
antibiot
without
evid
harm
reason
increas
singl
dose
brief
cours
translat
overal
reduct
durat
antibiot
like
relat
uniformli
high
use
prolong
antibiot
certain
clinic
group
especi
patient
pneumonia
mean
durat
around
day
affect
poct
subgroup
analys
suggest
increas
singl
dose
brief
cours
antibiot
occur
mainli
patient
exacerb
airway
diseas
group
poct
associ
signific
reduct
antibiot
durat
analysi
also
suggest
reduct
antibiot
use
occur
mainli
patient
test
posit
respiratori
virus
posit
test
reduc
antibiot
durat
lead
clinician
stop
antibiot
earlier
singl
dose
brief
cours
day
rather
complet
standard
day
cours
although
prematur
discontinu
antibiot
cours
previous
regard
inadvis
owe
concern
gener
resist
evid
suggest
earli
discontinu
safe
perspect
fact
associ
reduc
risk
drug
resist
around
patient
hospitalis
exacerb
asthma
copd
combin
year
uk
two
third
patient
treat
antibiot
therefor
conserv
regard
effect
size
reduct
antibiot
durat
around
day
per
patient
treat
would
equat
total
reduct
around
antibiot
day
per
year
reduct
would
contribut
substanti
antimicrobi
reduct
target
set
nation
health
servic
nh
organis
address
threat
antimicrobi
resist
although
trial
first
larg
randomis
control
trial
molecular
poct
respiratori
virus
examin
antibiot
use
detail
smaller
studi
suggest
potenti
strategi
reduc
antibiot
use
addit
chang
antibiot
use
studi
show
poct
might
associ
reduct
hospit
length
stay
subgroup
analys
suggest
reduct
also
princip
patient
exacerb
airway
diseas
data
suggest
result
due
earlier
discharg
patient
test
posit
respiratori
virus
poct
group
notabl
durat
hospitalis
copd
control
group
consist
quot
larg
contemporan
uk
studi
reduct
length
stay
patient
exacerb
airway
diseas
order
day
would
equat
around
bed
day
save
per
year
across
nh
associ
cost
save
around
million
per
year
formal
health
econom
analysi
trial
publish
separ
routin
poct
respiratori
virus
also
associ
increas
rate
detect
influenza
case
improv
antivir
use
although
patient
clinic
suspect
infect
test
control
group
lower
detect
rate
compar
poct
group
suggest
mani
case
influenza
miss
remain
undiagnos
group
result
unsurpris
physiciandiagnos
influenza
well
known
insensit
method
case
detect
even
period
high
influenza
activ
view
potenti
consequ
includ
nosocomi
spread
unrealis
opportun
benefit
neuraminidas
inhibitor
treatment
undiagnos
influenza
data
suggest
influenza
test
routin
done
patient
hospitalis
acut
respiratori
ill
period
influenza
circul
neuraminidas
inhibitor
treatment
recommend
uk
public
health
england
patient
hospitalis
influenza
although
treatment
recommend
irrespect
durat
ill
neuraminidas
inhibitor
like
effect
administ
earlier
cours
infect
studi
show
poct
respiratori
virus
lead
increas
proport
influenzaposit
patient
correctli
receiv
treatment
neuraminidas
inhibitor
suggest
reduc
time
administr
first
dose
addit
neuraminidas
inhibitor
use
direct
toward
influenzaposit
patient
poct
group
wherea
use
empir
control
group
led
mani
influenzaneg
patient
receiv
neuraminidas
inhibitor
unnecessarili
neuraminidas
inhibitor
use
influenzaneg
ativ
patient
also
prolong
control
group
presum
due
long
turnaround
time
laboratori
pcr
compar
poct
unnecessari
neuraminidas
inhibitor
use
expos
patient
sideeffect
neuraminidas
inhibitor
without
chanc
associ
benefit
improv
neuraminidas
inhibitor
use
seen
studi
consist
find
previou
nonrandomis
studi
hospitalis
adult
similar
differ
turn
around
time
rapid
test
laboratori
pcr
also
note
hospit
side
room
use
isol
potenti
infecti
patient
limit
resourc
uk
hospit
reassuringli
use
poct
respiratori
virus
lead
overal
increas
side
room
use
despit
increas
detect
rate
respiratori
virus
howev
side
room
isol
confirm
respiratori
viru
infect
common
poct
group
control
group
result
reflect
high
rate
direct
use
side
room
patient
confirm
influenza
virus
compar
empir
use
side
room
control
group
mani
subsequ
test
neg
deisol
poct
also
associ
improv
side
room
use
includ
reduc
time
admiss
isol
confirm
influenza
reduc
time
deisol
patient
isol
suspect
influenza
subsequ
test
neg
rapid
appropri
assign
hospit
side
room
patient
respiratori
viru
infect
huge
import
reduc
risk
nosocomi
transmiss
vulner
hospitalis
patient
improv
flow
patient
acut
area
within
hospit
molecular
poct
result
respiratori
virus
therefor
expect
directli
influenc
patient
manag
sever
way
posit
result
identifi
need
isol
facil
neuraminidas
inhibitor
use
case
influenza
although
detect
viru
rule
possibl
bacteri
infect
benefit
antibiot
posit
result
might
also
allow
prematur
discontinu
precautionari
antibiot
patient
exacerb
airway
diseas
requir
basi
criteria
sever
ill
neg
poct
result
prevent
shorten
unnecessari
use
isol
facil
neuraminidas
inhibitor
strength
studi
includ
larg
number
patient
recruit
set
typic
larg
acut
hospit
pragmat
design
broad
inclus
criteria
repres
typic
patient
admit
uk
secondari
care
simpl
intervent
comparison
routin
clinic
care
studi
also
took
place
two
winter
season
differ
pattern
influenza
activ
factor
suggest
find
studi
like
generalis
similar
uk
intern
centr
retrospect
choic
primari
outcom
measur
ideal
assess
effect
poct
antibiot
use
process
care
patient
acut
respiratori
ill
present
hospit
lead
patient
start
antibiot
earli
cours
assess
often
result
poct
could
made
avail
therefor
result
poct
abl
influenc
primari
outcom
larg
proport
patient
apriori
secondari
outcom
measur
durat
antibiot
use
proport
patient
treat
singl
dose
brief
cours
antibiot
arguabl
relev
standard
clinic
manag
groupantibiot
start
earli
patient
acut
respiratori
ill
might
subsequ
continu
discontinu
base
test
result
clinic
cours
posthoc
analysi
patient
yet
given
antibiot
poct
result
avail
arguabl
examin
slightli
differ
popul
primari
outcom
patient
clinician
feel
necessari
start
antibiot
earli
howev
reduct
antibiot
use
poct
group
compar
control
group
subgroup
give
credibl
antibiot
reduct
seen
main
studi
suggest
poct
even
earlier
point
might
reduc
unnecessari
antibiot
use
studi
weak
singlecentr
studi
addit
power
specif
detect
differ
subgroup
attempt
made
blind
anyon
studi
analyst
purpos
studi
inform
clinic
team
poct
result
could
blind
group
particip
randomis
patient
collect
data
could
blind
use
sham
swab
howev
felt
risk
bia
due
nonblind
low
find
ideal
replic
studi
definit
conclus
made
studi
took
place
winter
month
respiratori
viru
infect
common
find
extrapol
outsid
period
trial
poct
done
research
staff
rather
clinician
uncertainti
remain
test
could
deliv
routin
sever
model
deliveri
potenti
possibl
includ
train
clinician
nurs
staff
test
attend
consumpt
time
develop
poct
hub
within
acut
area
staf
dedic
technician
link
centralis
laboratori
conclus
routin
molecular
poct
respiratori
virus
adult
present
secondari
care
acut
respiratori
ill
improv
turnaround
time
result
detect
rate
respiratori
virus
reduc
proport
patient
treat
antibiot
overal
durat
antibiot
use
howev
routin
molecular
poct
associ
increas
proport
patient
receiv
singl
dose
brief
cours
antibiot
reduc
length
hospit
stay
improv
use
neuraminidas
inhibitor
influenza
improv
use
hospit
isol
facil
appear
safe
find
reproduc
studi
associ
health
econom
benefit
routin
molecular
poct
virus
introduc
diagnost
pathway
acut
respiratori
ill
adult
present
hospit
winter
month
twc
review
medic
literatur
conceiv
design
studi
supervis
studi
particip
data
analysi
interpret
draft
wrote
manuscript
njb
review
medic
literatur
particip
trial
design
recruit
patient
gener
collect
data
draft
wrote
manuscript
akm
la
rh
en
sa
pjl
recruit
patient
gener
collect
data
se
design
statist
analysi
analys
data
author
review
contribut
report
develop
declar
compet
interest
